Dr Kryshani Fernando

Job title

Consultant neurologist

Qualifications

MA MBBChir (Cantab) MRCP (UK) PhD

GMC Number

4373122

Contact details

Email address: kryshani.fernando@nhs.net

PA/secretary phone number: 020 7830 2387

PA/secretary email address: ross@nhs.net

Fax: 020 7472 6829

Related services

Neurosciences

Biography

Dr Kryshani Fernando has worked as a consultant neurologist at the Royal Free hospital and Watford General hospital since February 2010. She is the site lead for undergraduate neurology teaching. 
 

Publications

  • “Early prognosis in Multiple Sclerosis”  Josephine Swanton, Kryshani Fernando, David Miller, Handbook of Clinical Neurology: Multiple Sclerosis Volume (Elsevier 2014) Volume 122:371-391
  • Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis. Fernando KTM, McLean MA, Chard DT, MacManus DG, Dalton CM, Miszkiel KA, Gordon RM, Plant GT, Thompson AJ, Miller DH. Brain. 2004:127:1361-9.      
  • Magnetization transfer histograms in clinically isolated syndromes suggestive of multiple sclerosis.Fernando KTM, Tozer DJ, Miszkiel KA, Gordon RM, Swanton JK, Dalton CM, Barker GJ, Plant GT,  Thompson AJ, Miller DH. Brain.2005:128:2911-25. 
  • Selective magnetization transfer ratio decrease in the visual cortex following optic neuritis.Audoin B, Fernando KTM, Swanton JK, Thompson AJ, Plant GT, Miller DH. Brain 2006;129:1031-9.
  • Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Dalton CM, Chard DT, Davies GR, Miszkiel KA, Altmann DR, Fernando K, Plant GT, Thompson AJ, Miller DH. Brain 2004 ;127:1101-7. 
  • MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study. Korteweg T, Tintore M, Uitdehaag B, Rovira A, Frederiksen J, Miller D, Fernando K, Filippi M, Agosta F, Rocca M, Fazekas F, Enzinger C, Matthews P, Parry A, Polman C, Montalban X, Barkhof F. Lancet Neurology 2006;5:221-7
  • New T2 lesions enable an earlier diagnosis of multiple sclerosis in clinically isolated syndromes.Dalton CM, Brex PA, Miszkiel KA, Fernando K, MacManus DG, Plant GT, Thompson AJ, Miller DH. Annals of Neurology 2003; 53: 673-6. 
  • MRI outcomes in a placebo-controlled trial of natalizumab in relapsing Multiple Sclerosis.Miller DH, Soon D, Fernando KT, MacManus DG, Barker GJ, Yousry TA, Fisher E, O'Connor PW, Phillips JT, Polman CH, Kappos L, Hutchinson M, Havrdova E, Lublin FD, Giovannoni G, Wajgt A, Rudick R, Lynn F, Panzara MA, Sandrock AW. AFFIRM Investigators.Neurology 2007:68:1390-401.
  • Early MRI in optic neuritis: the risk for disability.Swanton JK, Fernando KT, Dalton CM, Miszkiel KA, Altmann DR, Plant GT, Thompson A J, Miller DH. Neurology 2009:72:542-50.
  • Cognitive impairment in Multiple Sclerosis can be predicted by imaging early in the disease.Summers M, Swanton J, Fernando K, Dalton C, Miller DH, Cipolotti L, Ron MA. J Neurol Neurosurg Psychiatry 2008:79:955-8.
  • Modification of MRI criteria for Multiple Sclerosis in patients with clinically isolated syndromes.
  • Swanton JK, Fernando KTM, Dalton CM, Miszkiel KA, Thompson AJ, Plant GT, Miller DH. J Neurol Neurosurg Psychiatry 2006:77:830-3.                                           
  • Is the frequency of abnormalities on magnetic resonance imaging in isolated optic neuritis related to the prevalence of multiple sclerosis? A global comparison.Swanton JK, Fernando K, Dalton CM, Miszkiel KA, Thompson AJ, Plant GT, Miller DH. J Neurol Neurosurg Psychiatry 2006:77:1070-2.
  • Spinal cord MRI in clinically isolated optic neuritis.Dalton CM, Brex PA, Miszkiel KA, Fernando K, MacManus DG, Plant GT, Thompson AJ, Miller DH. J Neurol Neurosurg Psychiatry. 2003:74:1577-80.
  • Cerebral atrophy measurement in clinically isolated syndromes and relapsing remitting multiple sclerosis: a comparison of registration-based methods. Anderson VM, Fernando KT, Davies GR, Rashid W, Frost C, Fox NC, Miller DH. J Neuroimaging 2007:17:61-8
  • Early MRI in optic neuritis: the risk for clinically definite multiple sclerosis.Swanton JK, Fernando KT, Dalton CM, Miszkiel KA, Altmann DR, Plant GT, Thompson A J, Miller DH. Mult Scler 2010:16:156-65
  • No evidence for MSRV viraemia and glial cell death in acute optic neuritis. Petzold A, Perron H, Fernando KTM, Plant GT.Mult Scler 2005;11:495-6. 
  • Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis. Lim ET, Berger T, Reindl M, Dalton CM, Fernando K, Keir G, Thompson EJ, Miller DH, Giovannoni G. Mult Scler 2005:11:492-4.
  • A study of subtle blood brain barrier disruption in a placebo-controlled trial of natalizumab in relapsing remitting multiple sclerosis. Soon D, Altmann DR, Fernando KT, Giovannoni G, Barkhof F, Polman CH, O'Connor P, Gray B, Panzara M, Miller DH. J Neurol 2007:254:306-14.
  • A three-year, multi-parametric MRI study in patients at presentation with CIS. Rocca MA, Agosta F, Sormani MP, Fernando K, Tintore M, Korteweg T, Tortorella P, Miller DH, Thompson A, Rovira A, Montalban X, Polman C, Barkhof F, Filippi M. J Neurol 2008:255:683-91.
  • A search for new MRI criteria for dissemination in space in subjects with a clinically isolated syndrome.Korteweg T, Tintore M, Uitdehaag BM, Knol DL, Vrenken H, Rovira A, Frederiksen J, Miller DH, Fernando K, Filippi M, Agosta F, Rocca MA, Fazekas F, Enzinger C, Parry A, Polman CH, Montalban X, Barkhof F. Eur Radiol.2009:19:2244-8.